Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday.
ORKA has been the topic of a number of other research reports. BTIG Research began coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They set a "buy" rating on the stock. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $40.38.
View Our Latest Stock Report on ORKA
Oruka Therapeutics Trading Down 2.5%
NASDAQ:ORKA opened at $11.68 on Friday. The stock has a market capitalization of $437.30 million, a PE ratio of -2.59 and a beta of -0.38. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $31.13. The firm has a fifty day simple moving average of $10.76 and a 200 day simple moving average of $12.76.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. On average, equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oruka Therapeutics
A number of large investors have recently made changes to their positions in ORKA. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics during the 4th quarter worth approximately $54,000. Squarepoint Ops LLC bought a new position in Oruka Therapeutics during the 4th quarter worth $236,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth $303,000. AlphaQuest LLC acquired a new stake in shares of Oruka Therapeutics during the first quarter worth $168,000. Finally, Jane Street Group LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $343,000. Institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
